Sappanone A 是一种从 sappan L 中发现的具有口服活性的同型异黄烷酮,作为 PDE4 和 NF-κB 抑制剂具有抗炎和抗氧化作用,可通过激活 Nrf2 通路诱导 HO-1 表达,还能抑制 RANKL 诱导的破骨细胞生成,在炎症相关和心血管疾病的研究中具有很大的潜力。
产品编号: MS-Q56750 纯度: 99.87% CAS No.: 102067-84-5 分子式: C16H12O5 分子量: 284.26
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Sappanone A 是一种从 sappan L 中发现的具有口服活性的同型异黄烷酮,作为 PDE4 和 NF-κB 抑制剂具有抗炎和抗氧化作用,可通过激活 Nrf2 通路诱导 HO-1 表达,还能抑制 RANKL 诱导的破骨细胞生成,在炎症相关和心血管疾病的研究中具有很大的潜力。

生物实验数据

生物活性 Sappanone A is an orally active homoisoflavanone discovered from sappan L. that acts as a PDE4 and NF-κB inhibitor with anti-inflammatory and antioxidant effects, induces HO-1 expression by activating the Nrf2 pathway, inhibits RANKL-induced osteoclastogenesis, and shows great potential in research on inflammation-related and cardiovascular diseases.
体外研究
(In Vitro)

Sappanone A (5-30 μM,预处理 1 h,再处理 24 h) 在 RAW264.7 细胞中以浓度依赖性方式抑制 LPS 诱导的 NO、IL-6 和 PGE 2产生 (IC50 分别为 6.8、11.2 和 12.6 μM),且无细胞毒性。
Sappanone A (5-30 μM,24 h) 在 RAW264.7 细胞中通过激活 Nrf2 诱导 HO-1 表达和抑制 LPS 诱导的 NF-κB 的活化,发挥抗炎作用。
Sappanone A (0-50 μM) 显著抑制 PDE4 酶活性,降低 RAW264.7 巨噬细胞中 LPS 诱导的 TNF-α 产生。
Sappanone A (0.007-1.0 mM,40 min) 具有优异的还原 Fe3+ 和络合 Fe2+ 能力,显示出优异的抗氧化活性。
Sappanone A (3-30 μM,7 days) 抑制 RANKL 诱导的小鼠 bone marrow-derived macrophage (BMM) 破骨细胞生成。
Sappanone A (0-30 μM,7 days) 抑制 BMM 中 RANKL 诱导的 NFATc1 激活和 AKT 磷酸化。
Sappanone A (10-30 μM,预处理 1 小时,再处理 24 小时) 在 HG 诱导的肾小球系膜细胞模型中,阻断 NF-κB 通路抑制炎症反应。

RT-PCR

Cell Line: RAW264.7cells
Concentration: 5, 15, 30 μM
Incubation Time: 24 h
Result: Reduced the mRNA levels of iNOS, COX-2, and IL-6 in a concentration-dependent manner.
Increased HO-1 mRNA expression level in a concentration-dependent manner, and HO-1 mRNA increased 3 hours after treatment, peaked at 6 hours, and returned to basal levels at 24 hours.
Induced HO-1 expression by activating Nrf2, resulting in a concentration-dependent increase in the mRNA levels of NQO1 and GCLC.

Western Blot Analysis

Cell Line: BMM cells
Concentration: 0, 3, 10, 30 μM
Incubation Time: 7 days
Result: Increased the phosphorylation levels of ERK, p38 and JNK mitogen-activated protein kinases (MAPKs) in a time-dependent manner and pretreatment.
Inhibited RANKL-induced NFATc1 expression.
体内研究
(In Vivo)

Sappanone A (20, 50 mg/kg,i.p.,单次给药) 在 LPS 诱导的 C57BL/6 小鼠模型中保护小鼠免于死亡。
Sappanone A (50, 100 mg/kg,i.p.,每天两次,连续七天) 显著减轻 LPS 诱发的小鼠急性肺损伤 (ALI),且无明显毒副作用。
Sappanone A (50 mg/kg,i.p.,一天隔一天注射,共注射八天) 在 LPS 诱导的小鼠骨质流失模型中,对体内破骨细胞形成有抑制作用。
Sappanone A (20 mg/kg,i.p.,单次给药) 在心肌缺血再灌注损伤 (MIRI) 大鼠模型中,可减少心肌坏死和细胞凋亡,促进心脏功能的恢复。
Sappanone A (10-30 mg/kg,i.g.,一天一次,连续十二周) 在 Streptozotocin (MS-Q80520) 诱发的糖尿病小鼠模型中,剂量依赖性的方式减轻高血糖期间的肾脏损伤。

Animal Model: ALI in Institute of Cancer Research mice (male 20-25 g) was established by intratracheal instillation of 0.5 mg/kg LPS in 100 μl saline solution.
Dosage: 50,100 mg/kg
Administration: i.p., twice a day for seven consecutive days, 1 h prior to LPS injection
Result: Significantly reduced the production of TNF-α in lung tissue, protein content in BALF, and MPO activity.
Had a good effect on the growth, development and behavior of mice, and no death or obvious toxic side were observed.
Animal Model: Institute of Cancer Research mice (male 6 weeks) injected with LPS (5 mg/kg)
Dosage: 50 mg/kg
Administration: i.p., injected every other day for a total of eight days
Result: LPS-induced significant decreased in the number of TRAP-positive osteoclasts.
Had a good effect on the growth, development and behavior of mice, and no death or obvious toxic side were observed.
Animal Model: Wistar rats (male 250 g) MIRI model (hearts were isolated and underwent 30-min ischemia, followed by 120-min reperfusion)
Dosage: 20 mg/kg
Administration: i.p., one dose, 1 h prior to heart isolation
Result: Reduce myocardial ischemia-reperfusion injury and myocardial infarction area.
Significantly improved LVDP and ±dp/dt values at 30, 60, and 120 min of reperfusion, indicating that it promoted the recovery of cardiac function after ischemia-reperfusion.
Inhibited ischemia-reperfusion-induced cardiomyocyte apoptosis by reducing cell apoptosis and inhibited the expression of cleaved caspase-3.
Significantly reduced the content of ROS and MDA in ischemic myocardium, and increased the activity of SOD and GSH-Px in ischemic myocardium.
Downregulated the expression of Keap1, decreased the level of Nrf2 in the cytoplasm, and increased the level of Nrf2 in the nucleus, and also activated the transcriptional activity to upregulate the expression of Nrf2 target genes (HO-1 and NQO1).
Enhanced the phosphorylation of Nfr2 through the PKC or PI3K pathway.
Animal Model: Streptozotocin (50 mg/kg, i.p., 5 consecutive days) induced diabetic C57BL/6J mice (20-23 g, 6-8 weeks)
Dosage: 10, 20, 30 mg/kg
Administration: i.g., once a day for twelve consecutive weeks
Result: Showed that the increase of serum creatinine and BUN was significantly attenuated, and the 24-hour urine protein of mice was significantly reduced.
Alleviated the pathological changes in Streptozotocin-treated mice, reduced the production of fibrotic molecules transforming growth factor β1 (TGF-β1) and collagen IV (Col-IV), and decreased the expression of inflammatory cytokines interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α).
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 284.26
分子式 C16H12O5
CAS No. 102067-84-5

储存&溶解度

体内实验配方
10% DMSO+90% Saline: < 10 mg/mL (35.18 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (35.18 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (351.79 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.5179 mL17.5895 mL35.1791 mL87.9477 mL
5 mM0.7036 mL3.5179 mL7.0358 mL17.5895 mL
10 mM0.3518 mL1.7590 mL3.5179 mL8.7948 mL
15 mM0.2345 mL1.1726 mL2.3453 mL5.8632 mL
20 mM0.1759 mL0.8795 mL1.7590 mL4.3974 mL
25 mM0.1407 mL0.7036 mL1.4072 mL3.5179 mL
30 mM0.1173 mL0.5863 mL1.1726 mL2.9316 mL
40 mM0.0879 mL0.4397 mL0.8795 mL2.1987 mL
50 mM0.0704 mL0.3518 mL0.7036 mL1.7590 mL
60 mM0.0586 mL0.2932 mL0.5863 mL1.4658 mL
80 mM0.0440 mL0.2199 mL0.4397 mL1.0993 mL
100 mM0.0352 mL0.1759 mL0.3518 mL0.8795 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

Sappanone A 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础